PARIS PARIS--(BUSINESS WIRE)-- Sanofi-aventis (Paris:SAN) (NYSE:SNY), one of the world’s largest diversified healthcare companies, reports results for the third-quarter of 2010. Jérôme Contamine, Chief Financial Officer of sanofi-aventis, comments on earnings and outlook.
Click to watch the video:
Topics covered in the interview include:
- Q3 earnings
- 2010 full year guidance
- Lovenox®
- New launches (Jevtana®, Multaq®)
- Seasonal flu vaccines
- Eloxatin®
- lixisenatide for Diabetes
- teriflunomide for Multiple Sclerosis
- US healthcare reform and EU price cuts
- Cost savings
- Patent cliff
About sanofi-aventis:
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Company website: http://en.sanofi-aventis.com/home.asp
CONTACT:
Investor Relations : [email protected]
or
Media Relations : [email protected]
KEYWORDS: Europe France
INDUSTRY KEYWORDS: Health Pharmaceutical Research Science
MEDIA:
| Logo |